Literature DB >> 28833209

A study of 853 high grade osteosarcomas from a single institution-Are outcomes in Indian patients different?

Ajay Puri1, Suman Byregowda1, Ashish Gulia1, Saniya Crasto1, Girish Chinaswamy1.   

Abstract

AIMS: To review outcomes of 853 patients of primary high grade osteosarcoma operated with curative intent between January 2006 to December 2013.
METHODS: All patients underwent appropriate surgical resection after preoperative chemotherapy (non methotrexate based). Excised specimen was analyzed for margins and response to chemotherapy. We analysed various factors (sex, age, size, site, type of surgery, pathologic fractures, margin status, and chemotherapy induced necrosis) for their impact on outcomes.
RESULTS: Five year overall survival (OS) for entire cohort was 49% and event free survival (EFS) was 42%. Seventy hundred thirty-eight non metastatic patients had OS of 53% and EFS of 47% at 5 years. The 3 year OS and EFS of the metastatic patients was 22% and 9%, respectively. Analysis of 738 non metastatic patients demonstrated that chemotherapy induced necrosis, size of tumor (< / >8 cms), type of surgery (limb salvage vs amputation) significantly affected overall survival. Local recurrence was 9%. Site of tumor (long bone vs pelvis), type of surgery and chemotherapy induced necrosis influenced local recurrence.
CONCLUSIONS: Our patients appeared to have poorer survival compared to most Western data, possibly attributable to large tumors. In contrast to existing data, males (71%) were predominantly affected and only patients with 100% necrosis qualified as good responders regarding OS.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  bone sarcoma; chemotherapy necrosis; limb salvage

Mesh:

Year:  2017        PMID: 28833209     DOI: 10.1002/jso.24809

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

1.  Factors Affecting Prognosis and Survival in Extremity Osteosarcoma.

Authors:  Anvesh Dharanikota; Ravi Arjunan; Ashwathappa Dasappa
Journal:  Indian J Surg Oncol       Date:  2021-01-06

2.  Predictors and Treatment Outcomes of Pediatric Osteosarcoma in Diverse Socioeconomic Backgrounds in Southeast Asia: A Retrospective Multicenter Study.

Authors:  Chalinee Monsereenusorn; Ana Patricia Alcasabas; Amos Hong Pheng Loh; Shui Yen Soh; Kenneth Wong Pak Leung; Chetan Dhamne; Sally Blair; Catherine Lam; Piya Rujkijyanont; Chanchai Traivaree; Apichat Photia; Puwadon Veerapan; Mark E Puhaindran; Bernice L Z Oh; Edward Wang; Carlos Rodriguez-Galindo
Journal:  Asian Pac J Cancer Prev       Date:  2022-02-01

3.  Treatment-Related Prognostic Factors in Managing Osteosarcoma around the Knee with Limb Salvage Surgery: A Lesson from a Long-Term Follow-Up Study.

Authors:  Jianping Hu; Chunlin Zhang; Kunpeng Zhu; Lei Zhang; Tao Cai; Taicheng Zhan; Xiong Luo
Journal:  Biomed Res Int       Date:  2019-05-02       Impact factor: 3.411

4.  Clinical outcome of various limb salvage surgeries in osteosarcoma around knee: Megaprosthesis, extracorporeal irradiation and resection arthrodesis.

Authors:  Achmad Fauzi Kamal; Primadika Rubiansyah
Journal:  Ann Med Surg (Lond)       Date:  2019-04-24

5.  A population-based propensity-matched study of regional dissections in patients with metastatic osteosarcoma.

Authors:  Wenjuan Wang; Hongzhi Ding; Zhenyu Sun; Chen Jin; Yanhui Zhu; Xiang Wang
Journal:  J Orthop Surg Res       Date:  2020-03-13       Impact factor: 2.359

6.  Association of high PDPN expression with pulmonary metastasis of osteosarcoma and patient prognosis.

Authors:  Xincheng Wang; Wei Li; Jiaqi Bi; Jia Wang; Linying Ni; Qingtao Shi; Qinggang Meng
Journal:  Oncol Lett       Date:  2019-11-05       Impact factor: 2.967

7.  Does Reconstruction with Reimplantation of Sterilized Tumor Bone Provide Survival Benefit in Diaphyseal Osteosarcoma?

Authors:  Prakash Nayak; Ashish Gulia; Ajay Puri
Journal:  Sarcoma       Date:  2020-01-19

8.  Prognostic factors in osteosarcoma: A study level meta-analysis and systematic review of current practice.

Authors:  Sun Xin; Guo Wei
Journal:  J Bone Oncol       Date:  2020-02-21       Impact factor: 4.072

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.